Alnylam's AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam Pharmaceuticals announced new data analyses from the HELIOS-B Phase 3 study of its RNAi therapeutic, called AMVUTTRA (vutrisiran), presented at the Heart Failure Society of America/HFSA Annual Scientific Meeting 2025.

The findings showed a reduction in gastrointestinal/GI events, which is a multisystem manifestation of transthyretin-mediated amyloidosis cardiomyopathy/ATTR-CM. Compared to placebo, treatment with vutrisiran led to a 42% lower rate of GI events in the overall population, a 37% lower rate in the vutrisiran monotherapy group, and a 49% lower rate in the group treated with tafamidis at baseline.

Importantly, individual symptoms like diarrhea, nausea, and vomiting saw reductions of greater than 50% across all three groups, with the lower rate of GI events observed as early as three months into treatment. Vutrisiran is an RNAi therapeutic that achieves rapid knockdown of transthyretin/TTR, approved for treating the cardiomyopathy of wild-type or hereditary ATTR-CM and the polyneuropathy of hereditary ATTR-PN in adults.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotech company that discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.